Study S000860

The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus: A 12-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Single-center Trial With an Open-label Glimepiride Arm

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT00620282
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 49
Start: 2008-02
Primary completion: 2010-05
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: DRUG:liraglutide; DRUG:placebo; DRUG:glimepiride
Results posted: TRUE

Registered primary outcomes

Change in Acetylcholine (ACh)-Mediated Forearm Blood Flow (FBF) [week 0, week 12]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0023483	Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials. Jensen TM, Diabetes care	2015	Systematic review	PMID 25504028 DOI	registry reference RESULT:25504028
R0021859	The effect of liraglutide on endothelial function in patients with type 2 diabetes. Nandy D, Diabetes & vascular disease research	2014	Randomized trial	PMID 25212693 DOI	cites ClinicalTrials.gov:NCT00620282; registry reference RESULT:25212693
R0020069	A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Alves C, Diabetes research and clinical practice	2012	Systematic review	PMID 23010561 DOI	registry reference RESULT:23010561